![](https://3211ea.a2cdn1.secureserver.net/wp-content/uploads/2022/10/AKTX-Social-Post-MIDD-Program-v2-9.16.22-1024x536.png)
Akari’s robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses selected for Phase 3 Part A #nomacopan study in severe pediatric HSCT-TMA, currently underway. #TMA #FDA